Acrotech Biopharma Inc., the U.S.-based step-down subsidiary of India-headquartered Aurobindo Pharma Ltd., has secured approval from the U.S. Food and Drug Administration for ADQUEY™. The approval marks a significant advancement in the company’s dermatology portfolio. ADQUEY™ is a difamilast 1% ointment for mild-to-moderate atopic dermatitis. The treatment addresses a chronic inflammatory skin condition affecting millions worldwide. The FDA approved the ...